Rituxiver

Rituximab

Category:

Biologic

Biologic

Injectable

Injectable

Dosage form :

Vials

Doses :

100/500 mg

Short Description:

Rituxiver is a type of targeted cancer drug called a monoclonal antibody. Monoclonal antibodies target proteins on the surface of cancer cells. Rituxiver targets a protein called CD20. CD20 is found on white blood cells called B cells.

Product Introduction

THERAPEUTIC ACTION:
Antineoplastic agent, monoclonal antibody
INDICATIONS:
Non-Hodgkin Lymphoma (NHL)
In patients with stage III/IV follicular non-Hodgkin lymphoma who have not previously been treated, rituximab is indicatedin combination with chemotherapy.
In patients with follicular lymphoma who have responded to induction treatment, rituximab is indicated for maintenance treatment.
In patients with stage III/IV follicular non-Hodgkin lymphoma who are chemoresistant or in their second or posterior relapse after chemotherapy, rituximab is indicated as monotherapy.
In patients with CD20-positive diffuse large B-cell non-Hodgkin lymphoma, rituximab is indicated in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine,
and prednisolone).
In patients with chronic lymphocytic leukemia (CLL) who have not been previously treated or who have relapsed or have been refractory to a previous treatment, rituximab is indicated in combination with chemotherapy.

Evidence is limited on the efficacy and safety of treatment with rituximab in patients previously treated with monoclonal antibodies, including rituximab (whether alone or in combination with chemotherapy).
Rheumatoid arthritis (RA) In adult patients with severe active rheumatoid arthritis who have presented inadequate response or intolerance to other disease-modifying antirheumatic drugs (DMARDs), including one or more treatments with tumor necrosis factor (TNF) inhibitors.
Rituximab in combination with methotrexate (MTX) is indicated for the treatment of rituximab has been shown to reduce the progression of joint damage measured by X-rays and to improve physical function when given in combination with methotrexate.
In adult patients with Wegener’s Granulomatosis (WG) and Microscopic Polyangiitis (MPA), rituximab is indicated in combination with glucocorticoids (MPA).

Bevacizumab

Biologic

Biologic

Oral

Oral